Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 1, pp 99–108 | Cite as

Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis

  • Tahmina Nasrin Poly
  • Md. Mohaimenul (Rubel) Islam
  • Hsuan-Chia Yang
  • Yu-Chuan Jack LiEmail author
Pharmacoepidemiology and Prescription

Abstract

Purpose

Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.

Methods

The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (n ≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).

Results

A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (I2 = 63.093, Q = 43.352, p < 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738–1.109), 0.96 (95%CI 0.882–1.055), and 0.99 (95%CI 0.841–0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated.

Conclusion

Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.

Keywords

Parkinson’s disease Non-steroidal anti-inflammatory drug Aspirin Ibuprofen Observational study 

Notes

Funding information

This work was financially supported by the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study has been approved by our Institution’s Ethics Committee and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Supplementary material

228_2018_2561_MOESM1_ESM.docx (209 kb)
ESM 1 (DOCX 209 kb)

References

  1. 1.
    Poly TN, Islam MM, Walther BA, Yang H-C, Nguyen P-A, Huang C-W, Shabbir S-A, Li Y-CJ (2017) Exploring the association between statin use and the risk of Parkinson’s disease: a meta-analysis of observational studies. Neuroepidemiology 49:142–151CrossRefGoogle Scholar
  2. 2.
    Le W, Wu J, Tang Y (2016) Protective microglia and their regulation in Parkinson’s disease. Front Mol Neurosci 9:89CrossRefGoogle Scholar
  3. 3.
    Solomon DH, Cannon CP, Saperia GM (2014) Nonselective NSAIDs: adverse cardiovascular effectsGoogle Scholar
  4. 4.
    Kurth T, Hennekens CH, Buring JE, Gaziano JM (2004) Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Curr Rheumatol Rep 6:351–356CrossRefGoogle Scholar
  5. 5.
    Hennekens CH, Knatterud GL, Pfeffer MA (2004) Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care 27:2752–2754CrossRefGoogle Scholar
  6. 6.
    Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 39:167–174CrossRefGoogle Scholar
  7. 7.
    Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58:963–967CrossRefGoogle Scholar
  8. 8.
    Bornebroek M, De Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM (2007) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193–196CrossRefGoogle Scholar
  9. 9.
    Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of Parkinson disease. Neurology 76:863–869CrossRefGoogle Scholar
  10. 10.
    Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18:S210–S212CrossRefGoogle Scholar
  11. 11.
    Maharaj D, Saravanan K, Maharaj H, Mohanakumar K, Daya S (2004) Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44:355–360CrossRefGoogle Scholar
  12. 12.
    Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635–1642CrossRefGoogle Scholar
  13. 13.
    Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966:245–252CrossRefGoogle Scholar
  14. 14.
    Przybyłkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Członkowska A, Członkowski A (2004) Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to mouse. Brain Res 1019:144–151CrossRefGoogle Scholar
  15. 15.
    Bower J, Maraganore D, Peterson B, Ahlskog J, Rocca WA (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67:494–496CrossRefGoogle Scholar
  16. 16.
    Samii A, Etminan M, Wiens MO, Jafari S (2009) NSAID use and the risk of Parkinson’s disease. Drugs Aging 26:769–779CrossRefGoogle Scholar
  17. 17.
    Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease a meta-analysis. Neurology 74:995–1002CrossRefGoogle Scholar
  18. 18.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefGoogle Scholar
  19. 19.
    Higgins JP, Green S (2005) Cochrane handbook for systematic reviews of interventions. versionGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefGoogle Scholar
  21. 21.
    Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A, Poly TN, Masud JHB, Li Y-CJ, Shabbir S-A (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47:181–191CrossRefGoogle Scholar
  22. 22.
    Becker C, Jick S, Meier C (2011) NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol 18:1336–1342CrossRefGoogle Scholar
  23. 23.
    Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064CrossRefGoogle Scholar
  24. 24.
    Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study. Bmj 342:d198CrossRefGoogle Scholar
  25. 25.
    Etminan M, Carleton BC, Samii A (2008) Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 15:576–577CrossRefGoogle Scholar
  26. 26.
    Etminan M, Suissa S (2006) NSAID use and the risk of Parkinson’s disease. Curr Drug Saf 1:223–225CrossRefGoogle Scholar
  27. 27.
    Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK (2007) Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64:576–580CrossRefGoogle Scholar
  28. 28.
    Hernán MA, Logroscino G, Rodríguez LAG (2006) Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66:1097–1099CrossRefGoogle Scholar
  29. 29.
    Lin CH, Wu RM, Chang HY, Chiang YT, Lin HH (2013) Preceding pain symptoms and Parkinson’s disease: a nationwide population-based cohort study. Eur J Neurol 20:1398–1404CrossRefGoogle Scholar
  30. 30.
    Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B (2011) Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease. Neuroepidemiology 36:155–161CrossRefGoogle Scholar
  31. 31.
    Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW (2008) Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 23:88–95CrossRefGoogle Scholar
  32. 32.
    Sung Y-F, Liu F-C, Lin C-C, Lee J-T, Yang F-C, Chou Y-C, Lin C-L, Kao C-H, Lo H-Y, Yang T-Y (2016) Reduced risk of Parkinson disease in patients with rheumatoid arthritis: a nationwide population-based study. Mayo Clinic Proceedings. Elsevier, pp 1346–1353Google Scholar
  33. 33.
    Ton TG, Heckbert SR, Longstreth W, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 21:964–969CrossRefGoogle Scholar
  34. 34.
    Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836–1842CrossRefGoogle Scholar
  35. 35.
    Kurkowska-Jastrzębska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A, Członkowska A (2002) Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2:1213–1218CrossRefGoogle Scholar
  36. 36.
    Mohanakumar KP, Muralikrishnan D, Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281–290CrossRefGoogle Scholar
  37. 37.
    Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NM (2017) Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst RevGoogle Scholar
  38. 38.
    Teismann P, Tieu K, Choi D-K, Wu D-C, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci 100:5473–5478CrossRefGoogle Scholar
  39. 39.
    Sánchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell A-L, Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 1:6CrossRefGoogle Scholar
  40. 40.
    Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Miller DS, Hong J-S (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19:1134–1136CrossRefGoogle Scholar
  41. 41.
    Carrasco E, Casper D, Werner P (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81:121–131CrossRefGoogle Scholar
  42. 42.
    Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24:121–132CrossRefGoogle Scholar
  43. 43.
    Bessone F (2010) Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol: WJG 16:5651–5661CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Graduate Institute of Biomedical Informatics, College of Medical Science and TechnologyTaipei Medical UniversityTaipeiTaiwan
  2. 2.International Center for Health Information Technology (ICHIT)Taipei Medical UniversityTaipeiTaiwan
  3. 3.Department of DermatologyWan Fang HospitalTaipeiTaiwan
  4. 4.TMU Research Center of Cancer Translational MedicineTaipeiTaiwan

Personalised recommendations